These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30870229)

  • 1. C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma.
    Di JX; Zhang HY
    Anticancer Drugs; 2019 Sep; 30(8):846-853. PubMed ID: 30870229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma.
    Bharadwaj U; Eckols TK; Xu X; Kasembeli MM; Chen Y; Adachi M; Song Y; Mo Q; Lai SY; Tweardy DJ
    Oncotarget; 2016 May; 7(18):26307-30. PubMed ID: 27027445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.
    Jung KH; Yoo W; Stevenson HL; Deshpande D; Shen H; Gagea M; Yoo SY; Wang J; Eckols TK; Bharadwaj U; Tweardy DJ; Beretta L
    Clin Cancer Res; 2017 Sep; 23(18):5537-5546. PubMed ID: 28533225
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
    Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
    Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/β-catenin Axis with HJC0152.
    Wang Y; Wang S; Wu Y; Ren Y; Li Z; Yao X; Zhang C; Ye N; Jing C; Dong J; Zhang K; Sun S; Zhao M; Guo W; Qu X; Qiao Y; Chen H; Kong L; Jin R; Wang X; Zhang L; Zhou J; Shen Q; Zhou X
    Mol Cancer Ther; 2017 Apr; 16(4):578-590. PubMed ID: 28138036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).
    Chakravarti N; Myers JN; Aggarwal BB
    Int J Cancer; 2006 Sep; 119(6):1268-75. PubMed ID: 16642480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling.
    Jia L; Song Q; Zhou C; Li X; Pi L; Ma X; Li H; Lu X; Shen Y
    PLoS One; 2016; 11(1):e0147157. PubMed ID: 26784960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Notch inhibitor, FLI-06, increases the chemosensitivity of head and neck Squamous cell carcinoma cells to taxanes-based treatment.
    Czerwonka A; Kałafut J; Wang S; Anameric A; Przybyszewska-Podstawka A; Toriseva M; Nees M
    Biomed Pharmacother; 2024 Aug; 177():116822. PubMed ID: 38906029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma.
    Lee JH; Rangappa S; Mohan CD; ; Sethi G; Lin ZX; Rangappa KS; Ahn KS
    Biomolecules; 2019 Sep; 9(10):. PubMed ID: 31575007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
    Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma.
    Dong L; Liu C; Sun H; Wang M; Sun M; Zheng J; Yu X; Shi R; Wang B; Zhou Q; Chen Z; Xing B; Wang Y; Yao X; Mei M; Ren Y; Zhou X
    Cancer Lett; 2024 Jul; 593():216956. PubMed ID: 38735381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effects of ML385 on Head and Neck Squamous Cell Carcinoma: Implications for NRF2 Inhibition as a Therapeutic Strategy.
    Jeong EJ; Choi JJ; Lee SY; Kim YS
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
    Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
    Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimetastatic Effects of Sesamin on Human Head and Neck Squamous Cell Carcinoma through Regulation of Matrix Metalloproteinase-2.
    Chen JM; Chen PY; Lin CC; Hsieh MC; Lin JT
    Molecules; 2020 May; 25(9):. PubMed ID: 32397656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction of interleukin-8 and PTEN inactivation promotes the malignant progression of head and neck squamous cell carcinoma via the STAT3 pathway.
    Xu Q; Ma H; Chang H; Feng Z; Zhang C; Yang X
    Cell Death Dis; 2020 May; 11(5):405. PubMed ID: 32471980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells.
    Lin HY; Hou SC; Chen SC; Kao MC; Yu CC; Funayama S; Ho CT; Way TD
    J Agric Food Chem; 2012 Mar; 60(10):2480-9. PubMed ID: 22313388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor growth suppression by inhibiting both autophagy and STAT3 signaling in HNSCC.
    Fan TF; Bu LL; Wang WM; Ma SR; Liu JF; Deng WW; Mao L; Yu GT; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(41):43581-93. PubMed ID: 26561201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
    Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
    Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
    Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
    J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.